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We conducted a retrospective
review of patients treated
with salvage radiosurgery
(SRS) for recurrent brain
metastases after prior brain
radiation therapy (RT) to
evaluate local control,
survival, and factors predic-
tive of these outcomes. On
multivariable analysis, age,
extracranial disease control,
and interval from initial RT
to salvage SRS of at least
265 days were predictive for
survival. Salvage SRS should
be considered for younger
patients with controlled
extracranial disease and
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Open access undPurpose: Stereotactic radiosurgery (SRS) is offered to patients for recurrent brain metastases
after prior brain radiation therapy (RT), but few studies have evaluated the efficacy of salvage
SRS or factors to consider in selecting patients for this treatment. This study reports overall sur-
vival (OS), intracranial progression-free survival (PFS), and local control (LC) after salvage
SRS, and factors associated with outcomes.
Methods and Materials: This is a retrospective review of patients treated from 2009 to 2011
with salvage SRS after prior brain RT for brain metastases. Survival from salvage SRS and from
initial brain metastases diagnosis (IBMD) was calculated. Univariate and multivariable (MVA)
analyses included age, performance status, recursive partitioning analysis (RPA) class, extracra-
nial disease control, and time from initial RT to salvage SRS.
Results: There were 106 patients included in the analysis with a median age of 56.9 years (range
32.5-82 years). Amedian of 2metastases were treated per patient (range, 1-12) with a median dose
of 21 Gy (range, 12-24) prescribed to the 50% isodose. With a median follow-up of 10.5 months
(range, 0.1-68.2), LC was 82.8%, 60.1%, and 46.8% at 6 months, 1 year, and 3 years, respectively.
Median PFS was 6.2 months (95% confidence interval [CI] Z 4.9-7.6). Median OS was 11.7
months (95% CIZ 8.1-13) from salvage SRS, and 22.1 months from IBMD (95% CIZ 18.4-
26.8). OnMVA, age (PZ.01; hazard ratio [HR]Z 1.04; 95%CIZ 1.01-1.07), extracranial disease
control (PZ.004;HRZ 0.46; 95%CIZ 0.27-0.78), and interval from initial RT to salvage SRS of
at least 265 days (PZ.001; HRZ 2.46; 95% CIZ 1.47-4.09) were predictive of OS.
Conclusions: This study demonstrates that patients can have durable local control and survival after
salvage SRS for recurrent brain metastases. In particular, younger patients with controlled extracra-
nial disease and a durable response to initial brain RT are likely to benefit from salvage SRS.
 2014 Elsevier Inc.Open access under CC BY-NC-ND license.RCPC, CIP, Department of
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Kurtz et al. International Journal of Radiation Oncology  Biology  Physics138Introduction All metastases were contoured by a physician, and treatment wasBrain metastases develop in approximately 20% to 40% of cancer
patients (1). They arise most commonly from primary lung, breast,
melanoma, and renal cell cancers, although nearly every malignancy
has the potential for intracranial involvement. Brain metastases are
associated with significant morbidity and impact on patients’ quality
of life as a result of neurological deficits, loss of independence,
seizures, steroid dependence, and death.
With advances in systemic therapies resulting in improved
survival and extracranial metastatic disease control, the incidence of
brain metastases is rising (2). The mainstays of therapy at the time of
initial diagnosis of brain metastases include surgery, whole-brain
radiation therapy (WBRT), and stereotactic radiosurgery (SRS),
alone or in combination (3). There are a number of randomized trials,
meta-analyses, and clinical practice guidelines to aid clinicians in the
management of brain metastases at first diagnosis (1,3-6).
However, there are limited data to guide the treatment of recurrent
intracranial disease (7). Treatment approaches for recurrent brain
metastases range from best supportive care to repeat WBRT, surgery,
or radiosurgery. The 2005 ASTROGuidelines stated that evidence for
salvage radiosurgery for brain metastases is limited and therefore did
not provide explicit recommendations for when patients should be
considered for this modality (6). The updated Guidelines (2012) did
not address the role of salvage therapy for recurrent brain metastases,
but did emphasize that this is an area worthy of further research (3).
Thus, the goal of this retrospective study is to report the outcomes of
salvage radiosurgery for recurrent brain metastases and to identify
clinical characteristics that can guide the selection of patients who
would most likely benefit from salvage SRS.Methods and Materials
Patient Selection
Research Ethics Board approval was obtained to conduct a review of
individuals 18 years or older treated with salvage SRS who met the
following criteria: (1) prior treatment with radiation therapy
(WBRT, intensity modulated radiation therapy [IMRT]), or SRS)
with orwithout surgery for 1 ormore intracranialmetastases; and (2)
recurrence of a previously treated brain metastases or development
of a new metastasis treated with salvage SRS between September
2009 and August 2011. Charts for eligible patients were reviewed
for the following information at the time of their diagnosis of
recurrent brainmetastases: (1) demographic data (age; performance
status, using the Eastern Cooperative Oncology Group (ECOG)
validated score; date of original magnetic resonance imaging [MRI]
or computed tomography [CT] scan that first identified intracranial
disease; date of death or date of last follow-up documented in the
patient’s chart; (2) tumor data (histology; extracranial disease
control [controlled vs uncontrolled]); and (3) treatment data (date
and type of first radiation treatment [RT]; time elapsed from initial
RT to salvage SRS; number of metastases treated at salvage SRS;
and volume of metastases treated at salvage SRS).
Radiosurgery Technique
All patients were immobilized with a Leksell stereotactic frame,
and treatment was delivered on a Gamma Knife radiosurgery unit.planned using GammaPlan software (Elekta, Stockholm, Sweden.)
As per institutional practice, metastases with volumes of less than
4 cc, between 4 and 10 cc, and between 10 and 20 cc were pre-
scribed 21 to 24 Gy, 18 Gy, and 15 Gy to the 46% to 70% isodose,
respectively. Metastases located in eloquent brain (brainstem,
motor strip) were treated with 15 Gy, and the dose between
adjacent lesions was limited to 13 Gy.
Statistical Analysis
Based on the Revised Assessment in Neuro-Oncology (RANO)
criteria, local control was defined as absence of radiological pro-
gression of the treatedmetastases, where progressionwas defined as
a minimum 25% increase in the sum of 2 diameters of the treated
metastasis, on contrast-enhanced MRI, taking as reference the
baseline sum, except when the increase in size was attributed to
radionecrosis or acute radiation effect (8). Progression-free survival
(PFS) was defined as the number of days from salvage SRS treat-
ment to date of local or intracranial progression or death. Overall
survival (OS) was calculated from salvage SRS to death. As a
separate statistic, survival was also calculated from date of initial
brain metastases diagnosis (IBMD) to death.
Survival estimates were calculated using the Kaplan-Meier
method. Group differences were examined using the logerank test.
Local progression ratewas calculated using the cumulative incidence
function, with group differences compared using Gray’s test (9, 10).
Univariate (UVA) and multivariable (MVA) analyses of OS and PFS
were performedusing theCox proportional hazardmodel. Prognostic
factors studied in UVA included age, performance status (ECOG),
extracranial disease control, intracranial disease control (a time-
varying variable), histology, recursive partitioning analysis (RPA)
class, and time from initial RT to salvage SRS. MVA included only
factors with P<.30 in UVA. The multivariable model was built using
backward elimination of variables with P0.05. All analyses used
SAS 9.2 and R 3.0.0 statistical software, and considered 2-sided
P<.05 as statistically significant.Results
From September 2009 to August 2011, a total of 114 patients were
seen inconsultation for salvageSRS.Eight patientswere excluded for
the following reasons: 2 ultimately did not receive salvage SRS, 3
received SRS after prior prophylactic cranial irradiation, and 3
received SRS for brain metastases after prior brain RT for skull base
and nasal bone metastases. Thus, 106 patients were included in the
analysis, of whom 70 were women (66%) and 36 were men (34%).
(Table 1) The median age of patients was 56.9 years (range, 32.5-82
years). The majority of patients were RPA class 2 (53.8%), followed
by class 1 (38.7%) and class 3 (5.7%). The majority of patients had
lung (51%) or breast (23%) primaries. In 87 of the 106 patients, status
of systemic therapy administration within 3 months of salvage SRS
could be determined. Of these 87 patients, 50 (57%) received
systemic treatment within 3 months of salvage SRS.
Median dose delivered to individual metastases was 21 Gy to
the 50% isodose (range: 12-24 Gy). In total, 279 metastases were
treated with a median of 2 metastases per patient (range: 1-12).
(Table 2)
The median duration of follow-up from date of salvage SRS
was 10.5 months (range, 0.1-68.2 months). Of the patients, 25%
Table 1 Patient demographics
Variable Category Frequency %
Sex Female 70 66
Male 36 34
Age Median: 56.9 years
(range, 32.5-82)
d d










ECOG 0, 1 87 82.1













WBRT þ SRS boost 5 4.7
Partial-brain (IMRT) 10 9.4
SRS 9 8.5
Unknown 1 0.9
Abbreviations: ECOG Z Eastern Cooperative Oncology Group;
IMRT Z intensity modulated radiation therapy; RPA Z recursive
partitioning analysis; SRS Z stereotactic radiosurgery; WBRT Z
whole-brain radiation therapy.
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months in this group.
Median LC of the treated metastases at 6 months, 1 year, and 3
years was 82.8%, 60.1%, and 46.8%, respectively. Median intra-
cranial PFS was 6.2 months (95% confidence interval [CI]Z 4.9-
7.6), with maintained intracranial control in 53.8% of patients at 6
months, and 23.1% at 1 year (Figure 1). On univariate analysis,
only time from initial RT to salvage SRS greater than the median
of 265 days was predictive of intracranial PFS (PZ.001, hazard
ratio [HR] Z 1.96, 95% CI Z 1.30-2.94). Neither number
(PZ.214) nor volume (PZ.389) of metastases was predictive of
intracranial PFS.
Median OS from time of salvage SRS was 11.7 months (95%
CI Z 8.1-13.0), with 16.3% of patients alive at 3 years post-Table 2 Treatment data
Variable Mean SD Median Minimum Maximum
Number of metastases
treated
3 2 2 1 12
Volume of metastases
treated (cm3)
4.00 3.85 2.42 0.04 14.80
Time from initial RT
to salvage SRS
(days)
341 310 265 28 1820
Abbreviations: RT Z radiation therapy; SD Z standard deviation;
SRS Z stereotactic radiosurgery.salvage treatment. On UVA, time from initial RT to salvage SRS
greater than the median of 265 days (PZ.001), extracranial dis-
ease controlled (PZ.013), and RPA class 1 (PZ.019) were pre-
dictive of improved OS. Neither number nor volume of metastases
was associated with better survival. Variables with P<.30 on UVA
were entered into the MVA. On MVA, younger age (PZ.01;
HRZ 1.04; 95% CIZ 1.01-1.07), time from previous RT greater
than the median 265 days (P<.001; HRZ 2.46; 95% CIZ 1.47-
4.09), and extracranial disease control (PZ.004; HRZ 0.46; 95%
CI Z 0.27-0.78) were significant predictors of OS (Table 3).
Of the 106 patients included in the analysis, date of IBMD was
available for 100 patients. Median survival from IBMD was 22.1
months (95% CI Z 18.4-26.8 months) (Figure 2). On UVA, RPA
class (PZ.05) and time from initial RT to salvage SRS (P<.001)
were associated with improved survival. Individuals in RPA class
1 had a median survival of 26.8 months from IBMD, compared
with 20.5 months for individuals in RPA classes 2 and 3. Duration
from initial RT to salvage SRS had the greatest impact on survival,
such that individuals with duration of less than the median of 265
days had a median survival of 14.9 months compared with 33.6
months for those with duration longer than 265 days (Table 4).
Twenty-one patients (19.8%) received additional courses of SRS
after initial salvage SRS, for further intracranial progression, of
whom 6 patients received a total of 3 courses of salvage SRS. Twelve
patients had subsequent surgery (including surgery for suspected
radionecrosis), and 18 had subsequent IMRT or WBRT.
Radionecrosis was identified in 9 patients (8.5%) during follow-
up.Diagnosis of radionecrosiswas based on contrast-enhancedMRI
if T1-weighted images demonstrated enhancement within the irra-
diated area, associated with central hypointensity of the lesion and
surrounding edema, and if the region of concernwas the same size or
smaller on imaging 3 months later without further radiation. This
radiological definition of radionecrosis has been similarly reported
(11). All patients were initially managed with oral corticosteroids.
Four patients eventually had surgery, and all resected lesions
contained findings of both tumor and radionecrosis.
Discussion
Historically, the diagnosis of brain metastases has been associated
with an extremely poor prognosis. However, in the last 2 decades,
this assumption has been challenged by novel systemic therapies
that are evolving the natural history of metastatic disease, and
advancements in radiation techniques for treating intracranial tu-
mors that have contributed to improved function and survival for
these patients. The goal of our study was to identify clinical
characteristics that can direct the selection of patients who would
most likely benefit from salvage SRS, and further advance the
evidence available to guide treatment for these patients.
Patients in our study were stratified by the RPA classification
system, which demonstrated that age, performance status, and the
status of extracranial disease affect the life expectancy of patients
with intracranial metastases (12). Irrespective of treatment mo-
dalities, the RPA classification estimates the median survival of
class 1 patients at 7.1 months, class 2 at 4.2 months, and class 3 at
2.3 months (12). More recently, the graded prognostic assessment
(GPA) score was introduced as a refined prognostic tool to classify
patients with brain metastases, based on a modern dataset,
including patients evaluated using MRI, and treated with modern
systemic therapy and radiosurgery (13). Adding tumor histology
to the GPA, the median survival among individuals with the most
Fig. 1. Overall survival and local control from salvage stereotactic radiosurgery (SRS). (a) Kaplan-Meier curve of OS from salvage SRS.
(b) LC from salvage SRS. (c) OS for patients with controlled versus uncontrolled extracranial disease. (d) OS for patients treated with
salvage SRS at <265 days versus >265 days from initial RT (WBRT, IMRT, or SRS) for brain metastases.
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longer than the earlier estimated survival of RPA class 1 patients,
ranging from 13.2 months (melanoma) to 25.3 months (breast
cancer) (13). This demonstrates that certain individuals with good
performance status can live more than 2 years with brain metas-
tases. Our results showing that RPA class 1 individuals had a
median survival of 26.8 months from initial brain metastases
diagnosis are consistent with recent reports, and demonstrate that
prior studies may underestimate the potential long-term survival
that young patients with good performance status and controlled
extracranial disease can achieve with current management.
In light of prolonged survival, it is essential to monitor intra-
cranial control with surveillance MRI after initial brain radiation
therapy in patients with good performance status and controlled
extracranial disease. If recurrent disease is identified, it is
important to consider the risks and benefits of various radiation
therapy options in the salvage setting. Radiosurgery is a highly
conformal treatment that can maximally spare normal tissue whileTable 3 Median overall survival and multivariable analysis of facto
Variable Group Median OS (mo) 95%
Performance status ECOG 0, 1 12.3 9.3
ECOG 2, 3 4.7 1.6
RPA class RPA 1 13.0 10.0
RPA 2 or 3 9.7 5.8
Time from RT to SRS <265 Days 7.9 5.7
265 Days 15.3 12.3
Extracranial disease Controlled 13.0 9.3
Uncontrolled 9.9 5.7
Age Continuous d d
Abbreviations: CIZ confidence interval; HRZ hazard ratio; MVAZ multi
RT Z radiation therapy; SRS Z stereotactic radiosurgery.effectively treating visible metastases, and may be the preferred
salvage treatment for patients with recurrent brain metastases after
prior WBRT. Although repeat WBRT is an option for salvage
treatment after prior WBRT, there is appropriate concern
regarding increased risk of neurotoxicity, as WBRT has been
associated with cognitive decline, particularly for individuals with
longer life expectancies (14). Although it has not been evaluated
in the salvage setting, initial stereotactic radiosurgery for brain
metastases has been suggested to be associated with less neuro-
cognitive toxicity compared with WBRT (5, 15, 16). Although
distant brain failure has historically been higher in patients treated
with radiosurgery alone, close follow-up and salvage therapy have
been suggested as a reasonable alternative management option to
address this potential concern (4).
Several studies have reported the efficacy of radiosurgery
after prior WBRT. In a review of patients treated with salvage
SRS from 1991 to 2007, Caballero et al reported a median sur-





(Wald test) HR 95% CI
14.6 .297 d d d d
15.1 . . . . .
23.3 .017 d d d d
12.8 . . . . .
10.2 <.001 <.001 2.46 1.47 4.09
21.8 . . . . .
17.0 .012 .004 0.46 0.27 0.78
12.8 . . . . .
d .274 .010 1.04 1.01 1.07
variable; OSZ overall survival; RPAZ recursive partitioning analysis;
Fig. 2. (a) OS from IBMD for patients with salvage stereotactic radiosurgery (SRS) delivered less than versus greater than the median
duration of 265 days from initial RT to salvage SRS. (b) OS from IBMD for patients in RPA class 1 versus RPA class 2 or 3.
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months where multiple metastases were present (17). An addi-
tional study by Chao et al of patients treated with salvage SRS
from 1989 to 2004 after initial WBRT reported a median survival
of 9.9 months (18). Our study is the first to report results of
salvage radiosurgery after prior SRS or WBRT. Our median
survival of 11.7 months was comparable to survival in these prior
reports. As expected, although our 1-year LC rate of 60.1% was
similar to that of Chao et al of 68%, the distant brain control rate
in the study by Chao et al was 86% at 1 year, whereas our
intracranial PFS was 23%. This reflects our inclusion of patients
treated initially with SRS alone or partial-brain IMRT, who
would likely experience higher rates of distant intracranial pro-
gression. We also found similar prognostic factors to those re-
ported in these prior studies, including younger age, longer
interval from initial radiation therapy to salvage SRS, and
controlled extracranial disease. Our findings also confirmed
those of Caballero et al that the absolute number of metastases
requiring salvage radiosurgery did not predict for survival, after
prior radiation therapy, whether this was WBRT or radiosurgery.
Chao et al identified time to recurrence from initial WBRT as the
main factor predictive of survival. Our study similarly found that
individuals who had more than 265 days (approximately 9
months) between initial radiation therapy and salvage SRS had a
longer median survival of 15.3 months after salvage SRS
compared with 7.9 months for those with a shorter duration
between initial radiation therapy and salvage SRS.
Despite the significant improvements in quality and quantity of
life that salvage radiosurgery can offer, our findings emphasize theTable 4 Median overall survival (OS) from date of initial brain me
Variable Group Total
All All 100
Performance Status ECOG 0, 1 83
ECOG 2, 3 17
RPA class 1 39




Extracranial control Controlled 55
Uncontrolled 36




Abbreviations: CI Z confidence interval; RPA Z recursive partitioning anaimportance of appropriate patient selection for this treatment. In the
absence of these positive prognostic factorsdyounger age,
controlled extracranial disease, and a durable response to initial
RTdsalvage SRS may not be beneficial and, in fact, may be inap-
propriate in some cases. Alternative palliative treatments and palli-
ative care should always be considered, as they can be instrumental in
managing the care of patients with recurrent brain metastases.
Nine patients in our cohort were found to have radionecrosis,
compared with 2 in the Chao et al study. All were initially
managed with oral corticosteroids, and of the 4 patients who had
surgical resection, the pathology showed a mixture of tumor and
radionecrosis. Evidence regarding radionecrosis after radiosurgery
and particularly salvage radiosurgery is limited, with reported
rates varying widely from 6% in the salvage setting (19) up to
24% after initial radiosurgery alone (11). This likely reflects a
combination of factors, including uncertainties in the diagnosis of
radionecrosis and variability in treated volume, cumulative radi-
ation dose to the brain, fractionation schedules of radiosurgery or
WBRT, patient survival after SRS, and time intervals between
treatments. Moving forward, improved evaluation of the toxicities
of radiosurgery for brain metastases is needed.Study limitations
As a retrospective study, there is inherent selection bias, as our
standard practice is to consider patients for salvage radiosurgery if
they have better prognostic factors such that their estimated life
expectancy is greater than 3 months. Patients were also oftentastases diagnosis
Median (95% CI) OS, mo P value (logerank)
22.1 (95% CI Z 18.4-26.8) d
21.9 (95% CI Z 18.2-26.9) .937
25.1 (95% CI Z 11.2-28.9) .
26.8 (95% CI Z 19.3-38.0) .050
20.5 (95% CI Z 15.6-24.2) .
24.0 (95% CI Z 17.5-36.9) .949
21.0 (95% CI Z 14.3-28.9) .
23.7 (95% CI Z 18.2-31.9) .
25.1 (95% CI Z 19.5-34.0) .070
19.3 (95% CI Z 14.6-24.2) .
14.9 (95% CI Z 12.1-18.0) <.001
33.6 (95% CI Z 26.9-48.1) .
lysis; RT Z radiation therapy; SRS Z stereotactic radiosurgery.
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improved local control, progression-free survival, and overall
survival. Conversely, these agents may have caused toxicities that
shortened their survival. Finally, aside from confirmed radio-
necrosis cases, quality of life and additional toxicity data were not
consistently collected. In future salvage SRS studies, it would be
important to collect these measures to optimize treatment and
patient selection, and to identify areas where supportive care can
be improved. Nevertheless, the patients included in this study
reflect the characteristic patients who are referred for consider-
ation of salvage SRS for recurrent brain metastases. These include
individuals with metastatic disease from a variety of histologies,
many of whom are on systemic therapy and maintaining good
performance status. Thus, the positive prognostic factors identified
in this study, associated with improved survival, are applicable to
patients being considered for salvage SRS with a range of his-
tologies in the era of modern systemic therapy.
Conclusions
There is a growing need to optimize approaches to salvage
treatment for recurrent brain metastases. This study demonstrates
that patients treated with salvage SRS for recurrent brain metas-
tases after prior WBRT, IMRT, or radiosurgery can have durable
survival, with a median survival of 11.7 months from salvage SRS
and a median survival of 22.1 months from IBMD. This is asso-
ciated with good local control of 60.1% at 1 year and 46.8% at 3
years. The key prognostic factors associated with better survival
include younger age, controlled extracranial disease, and longer
duration from initial brain metastases treatment to salvage SRS.
Individuals with at least 9 months’ duration from initial RT to
salvage SRS exhibited the best survival at 33.6 months from
IBMD. As systemic control and life expectancy of patients with
metastatic disease improves, salvage SRS should be considered
for younger patients with controlled extracranial disease, and
particularly those who have had a durable response to initial ra-
diation therapy for brain metastases.
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